INFOMED Blood purification devices ’s Post

You are interested in monitoring cellular immunity? 📢 Breaking News - @bioMérieux Life Sciences team will be at SSAI Annual congress 2024 in Geneva, Switzerland 📅 Come and join us on #Axonlab booth (30) on September 12th and 13th to learn more about our automated and standardized solutions to explore cellular immunity! More info on our solutions on our website : LIFE SCIENCES (biomerieux.com) #pionneringdiagnostics; #cellularimmunity

Study finds that CEUS can evaluate the severity of renal ischemia-reperfusion (IRI), as well as is proven to be a safe and effective technology in the detection of renal IRI in mice. (Zixin Xu et al.) #EuropeanRadiologyExperimental 🔗 https://buff.ly/3NZr4OQ

The Joint IRDiRC Consortium Assembly and Scientific Committees Meeting recently took place in China 🇨🇳 from May 22nd to May 23rd, setting the stage for groundbreaking discussions and collaborations to advance global rare disease research. 34 members were in attendance. The meeting was followed by the Global Rare Diseases Research Symposium and The Second China Rare Disease Research and Translational Medicine Annual Conference, co-hosted by IRDiRC, Hope for Rare Foundation, and Fudan University (复旦大学). This event featured 10 esteemed IRDiRC members, including Dave Pearce (Chair of IRDiRC), Emilio Roldán, Sally Ann Lynch, Ruty Mehrian-Shai, P.J. Brooks, Clara van Karnebeek (online), Ana Hidalgo-Simon, Daniel Scherman, Stefano Benvenuti, and Ramaiah Muthyala. The Consortium-Assembly Scientific Committees meeting set the tone for the subsequent symposium, fostering a spirit of innovation and collaboration. Together, we're pushing the boundaries of research to find solutions for those affected by rare diseases globally. 🌍🧬 #IRDiRC #RareDiseases #Research

🔬 Exciting News in Bioer's Molecular Point-of-Care Testing! 🔬 Thrilled to announce the breakthrough of Bioer's Molecular POCT Combo Test Panel, a cutting-edge solution for rapid and accurate detection of multiple respiratory pathogens. 🌐✨ 🦠 Comprehensive Pathogen Coverage: - Novel Coronavirus - Influenza A Virus - Influenza B Virus - Respiratory Syncytial Virus Subtype A - Respiratory Syncytial Virus Subtype B - Mycoplasma Pneumoniae - Adenovirus 🚀 Key Features: - Swift results for timely decision-making - High sensitivity and specificity - Streamlined workflow for efficient testing 🔍 Why Bioer's Molecular POCT Panel? Our panel goes beyond conventional qPCR testing, offering a complete molecular test workflow on chip with a focus on easy-to-use and speed. This is a crucial step forward in advancing research and enhancing our ability to respond effectively to respiratory challenges. 🌐 Stay at the Forefront of Research and Diagnosis: Bioer's commitment to innovation shines through in this Molecular POCT Combo Test Panel. Elevate your research capabilities and contribute to a healthier future. 🔗 Learn More: https://lnkd.in/gWHPir_t Join us in revolutionizing molecular diagnostics! Let's drive impactful research and create a healthier world together. 💙🌍 #Bioer #MolecularDiagnostics #POCT #ResearchInnovation #HealthcareAdvancements #RespiratoryPathogens #InfectiousDiseaseResearch

Join us in Malta for the First World Congress Targeting Extracellular Vesicles, organized by World Mitochondria Society & International Society of Microbiota! 📆 October 17-18, 2024 📍 Corinthia Palace, Malta Targeting EVs 2024 will explore the intricate interplay between extracellular vesicles, mitochondria, microbiota, and their implications for biomedical research and therapeutic interventions. 🎤 First Speakers Lineup: ramaroson andriantsitohaina, University of Montpellier, France Carla Lopes, Universidade de Coimbra, Portugal Devika S Manickam, Duquesne University, USA Didier Serteyn, University of Liège, Belgium Åsa B. Gustafsson, UC San Diego, USA Lanrong Bi, Michigan Technological University, USA Joachim Pius Spatz, Heidelberg University, Germany Consuelo Borras, University of Valencia, Spain Seyed Davar Siadat, Pasteur Institute of Iran, Iran 📩 Learn more in our March Newsletter: https://lnkd.in/dMzSUaVA 📨 Subscribe to receive the latest updates: https://lnkd.in/dMm8jZjd #TargetingExtracellularVesicles #TargetingEVs #extracellularvesicles #evs #exosomes #exosome #microbiome #microbiota #redox #iron #homeostasis #skin #mitochondria #ISM #WMS

For 30 years, Hytest has been at the forefront of cardiac troponin research, and we remain dedicated to scientific excellence in this field 🫀 🧑🔬 In our new study, we investigated the influence of heparin on the immunodetection of human cardiac troponins. 🔍 There is conflicting data regarding the effects of heparin on the measurement of cardiac isoforms of troponin I (cTnI) and troponin T (cTnT), which are used for the immunodiagnosis of acute myocardial infarction. 💡 The study concluded that heparin binds to the ITC-complex via cTnT, interacting with several sites on the N-terminal and/or central parts of the cTnT molecule, which might influence the immunodetection of analytes in human blood. Read more: https://lnkd.in/dycRf8xP #IVD #CardiacTroponin #heparin #AMI

One of the most talked about presentations at this year's #Bioprocessing Summit Europe is from Andreas Laustsen-Kiel at DTU - Technical University of Denmark talking about "Technical Challenges in Developing Monoclonal Antibodies Against Snake Venoms" by 🐍 Snakebite envenoming claims the lives of over 100,000 people each year. The only existing specific therapy against envenoming is antivenom based on polyclonal antibodies derived from the plasma of immunized animals, but these medicines are not compatible with the human immune system and may cause immunological adverse reactions. Additionally, they are expensive to manufacture. Find out more about this exciting work at the Bioprocessing Summit Europe, March 19-21, Barcelona - https://lnkd.in/eCrWaYG3 and the Nature paper: https://lnkd.in/e4cncHhe #chibioprocessingsummit #bioprocessing #snake #dtu #immunesystem

🔬 Exciting News in Bioer's Molecular Point-of-Care Testing (RUO)! 🔬 Thrilled to announce the breakthrough of Bioer's Molecular POCT Combo Test Panel, a cutting-edge solution for rapid and accurate detection of multiple respiratory pathogens. 🌐✨ 🦠 Comprehensive Pathogen Coverage: - Novel Coronavirus - Influenza A Virus - Influenza B Virus - Respiratory Syncytial Virus Subtype A - Respiratory Syncytial Virus Subtype B - Mycoplasma Pneumoniae - Adenovirus 🚀 Key Features: - Swift results for timely decision-making - High sensitivity and specificity - Streamlined workflow for efficient testing - Research Use Only (RUO) to empower innovative research initiatives 🔍 Why Bioer's Molecular POCT Panel? Our panel goes beyond conventional qPCR testing, offering a complete molecular test workflow on chip with a focus on easy-to-use and speed. This is a crucial step forward in advancing research and enhancing our ability to respond effectively to respiratory challenges. 🌐 Stay at the Forefront of Research and Diagnosis: Bioer's commitment to innovation shines through in this Molecular POCT Combo Test Panel. Elevate your research capabilities and contribute to a healthier future. 🔗 Learn More: https://lnkd.in/gWHPir_t Join us in revolutionizing molecular diagnostics! Let's drive impactful research and create a healthier world together. 💙🌍 #Bioer #MolecularDiagnostics #POCT #ResearchInnovation #HealthcareAdvancements #RespiratoryPathogens #InfectiousDiseaseResearch

One more day to submit your short talk and poster abstracts #EASD2024!

📢 We are thrilled to announce the launch of the first call for projects funded by the association LAMA2 France , with the support of Fondation Maladies Rares 👇🏼 🔬🧬 JOINT CALL FOR PROJECTS « Merosin-deficient Congenital muscular dystrophy» 🔎The aim of this call is to support any innovative research (basic or translational) aimed at the development of therapeutic strategies. All biomedical disciplines are eligible. This call should contribute to attract teams or researchers working on this disease, but also on other diseases where results could be transferred on #LAMA2 #CMD. 💰Max budget: 25 000 euro 🗓️Max duration: 24 months 🎯 Deadline: 05 september 2024, 5 pm (Paris time) ⁉️ https://lnkd.in/ege3rd9t #dmca1 #merosin #rarediseases #lama2europe Filnemus EURORDIS-Rare Diseases Europe